HC Wainwright Initiates Coverage on SOPHiA GENETICS (NASDAQ:SOPH)

Equities research analysts at HC Wainwright started coverage on shares of SOPHiA GENETICS (NASDAQ:SOPH) in a report issued on Monday, MarketBeat reports. The brokerage set a “buy” rating and a $12.00 price target on the stock. HC Wainwright’s target price indicates a potential upside of 84.62% from the stock’s current price.

A number of other analysts have also recently weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Tuesday, April 21st. BTIG Research reiterated a “buy” rating and set a $8.00 price objective on shares of SOPHiA GENETICS in a research note on Monday, June 15th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, SOPHiA GENETICS has an average rating of “Moderate Buy” and a consensus price target of $9.00.

SOPHiA GENETICS Trading Up 2.7%

Shares of NASDAQ SOPH opened at $6.50 on Monday. The company has a quick ratio of 1.90, a current ratio of 2.06 and a debt-to-equity ratio of 1.05. The stock’s 50 day moving average price is $5.30 and its two-hundred day moving average price is $5.05. SOPHiA GENETICS has a 52-week low of $2.92 and a 52-week high of $6.74. The stock has a market capitalization of $545.28 million, a P/E ratio of -12.50 and a beta of 0.96.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its earnings results on Tuesday, May 5th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.04). The firm had revenue of $21.69 million during the quarter, compared to analyst estimates of $20.40 million. SOPHiA GENETICS had a negative return on equity of 62.74% and a negative net margin of 44.48%.

Insider Activity

In other SOPHiA GENETICS news, CEO Ross Muken sold 9,838 shares of the firm’s stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $5.22, for a total transaction of $51,354.36. Following the transaction, the chief executive officer owned 670,651 shares of the company’s stock, valued at approximately $3,500,798.22. This trade represents a 1.45% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Zhenyu Xu sold 7,393 shares of the company’s stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $5.17, for a total transaction of $38,221.81. Following the completion of the sale, the insider directly owned 614,887 shares of the company’s stock, valued at approximately $3,178,965.79. This represents a 1.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 176,711 shares of company stock worth $959,913 in the last 90 days. 4.88% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On SOPHiA GENETICS

A number of institutional investors have recently added to or reduced their stakes in SOPH. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in SOPHiA GENETICS by 246.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock valued at $25,341,000 after purchasing an additional 5,432,871 shares in the last quarter. Akre Capital Management LLC raised its stake in shares of SOPHiA GENETICS by 66.2% in the 2nd quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock worth $11,529,000 after buying an additional 1,481,636 shares in the last quarter. Principal Financial Group Inc. lifted its holdings in shares of SOPHiA GENETICS by 0.7% in the first quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock valued at $6,976,000 after buying an additional 9,800 shares during the period. Archon Capital Management LLC lifted its holdings in shares of SOPHiA GENETICS by 3.4% in the fourth quarter. Archon Capital Management LLC now owns 441,413 shares of the company’s stock valued at $2,061,000 after buying an additional 14,342 shares during the period. Finally, Hodges Capital Management Inc. bought a new position in SOPHiA GENETICS during the first quarter valued at about $2,157,000. 31.59% of the stock is currently owned by institutional investors and hedge funds.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.